Advertisement

Topics

ESMO 2017: Combination immunotherapy in second/third line extends mesothelioma survival to 15 months

02:01 EDT 10 Sep 2017 | ecancermedicalscience

Combination immunotherapy as second or third line treatment extends overall survival to at least 15 months in patients with pleural malignant mesothelioma, according to late-breaking results from the MAPS2 trial presented at the ESMO 2017 Congress in...

Original Article: ESMO 2017: Combination immunotherapy in second/third line extends mesothelioma survival to 15 months

NEXT ARTICLE

More From BioPortfolio on "ESMO 2017: Combination immunotherapy in second/third line extends mesothelioma survival to 15 months"

Quick Search
Advertisement
 

Relevant Topic

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...